Unlock instant, AI-driven research and patent intelligence for your innovation.

An anti-vascular endothelial growth factor antibody and its fusion protein with hepcidin

A technology of endothelial growth factor and fusion protein, which is applied in the field of single-chain antibody and fusion protein with hepcidin, can solve the problems that the anti-tumor effect is difficult to achieve satisfactory results, and it is difficult to ensure synergistic effect, so as to achieve enhanced anti-tumor role, broaden the effect of anti-tumor

Active Publication Date: 2022-07-12
北京格根生物科技有限公司
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although bispecific antibodies have good tumor recognition ability, they often need to use other regulatory proteins or cells to promote the body to produce anti-tumor effects. Therefore, it is difficult to ensure efficient synergistic effects, and its anti-tumor effects are still difficult to achieve. Effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An anti-vascular endothelial growth factor antibody and its fusion protein with hepcidin
  • An anti-vascular endothelial growth factor antibody and its fusion protein with hepcidin
  • An anti-vascular endothelial growth factor antibody and its fusion protein with hepcidin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Preparation of anti-VEGF bispecific antibody

[0033] 1.1 Establishment of high-capacity natural antibody library.

[0034] Isolation of human peripheral blood mononuclear lymphocytes: 100 healthy adults were randomly selected, and 10ml of peripheral blood was drawn from each person. Dilute 1:1 with RPMI-1640 medium containing 10% heparin, add it to a centrifuge tube containing lymphocyte separation medium (the volume ratio of diluted venous blood and lymphocyte separation medium is 2:1), 2,000 × g, Centrifuge for 17 minutes. The milky white mononuclear cell layer at the interface of lymphocyte separation medium was aspirated and washed twice with PBS buffer.

[0035] 1.2 Extraction of total cell RNA

[0036] per 5 x 10 6 Trizol reagent was added at the ratio of cells / ml, and the cells were lysed by pipetting. Incubate at room temperature for 5 minutes, transfer to a DEPC-treated EP tube, add 1 / 5 volume of chloroform, shake vigorously for 15 seconds, and ...

Embodiment 2

[0077] Example 2. Construction of fusion protein

[0078] Hepcidin DNA and selected linker DNA were biosynthesized and ligated to VEGF ScFv DNA using PCR techniques.

[0079] PCR reaction system:

[0080]

[0081] Add deionized water to a final volume of 50 μl.

[0082] PCR parameters: After denaturation at 94°C for 3 minutes, PCR was performed at 94°C for 30 seconds; 61°C for 30 seconds; After the reaction, 5 µl of the reaction product was taken for analysis by 1% agarose gel electrophoresis.

[0083] Ligation reaction reaction system:

[0084]

[0085] The above-mentioned reactants were thoroughly mixed and centrifuged to sink to the bottom of the tube, and then ligated at 4°C overnight.

[0086] Transformation of recombinant plasmids (the same steps as before).

[0087] Sequence analysis of positive cloned DNA fragments.

[0088] The positive clones were identified by bacterial liquid PCR, and 1 ml of bacterial liquid was taken to complete the sequencing by Nosei ...

Embodiment 3

[0103] Example 3. Inhibitory effect of fusion protein on the growth of different breast cancer cells

[0104] Use Transwell chamber (type 3428, pore size 8um, Corning-Costar, USA) to measure cell invasiveness in vitro (according to the operating instructions)

[0105] Preparation of conditioned medium (as chemokine): mouse fibroblast cell line NIH3T3, cultured with RPMI-1640 medium containing 10% calf serum at 37°C, 5% CO2, and replaced with serum-free when the growth is good After culturing the culture solution for 24 hours, the supernatant was collected, sterilized by filtration, and frozen for later use.

[0106] 200ul / well of extracellular matrix was coated on the bottom of the Transwell chamber and polymerized in a 37°C incubator for 1 hour.

[0107] 1 ml of high-glucose DMEM medium containing 0.1% BSA was added to the 6-well plate to hydrate the basement membrane at 37°C for 30 minutes.

[0108] Aspirate the culture medium and add 2.5ml of 1:1 conditioned medium and co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-vascular endothelial growth factor single-chain antibody and a protein fused with hepcidin protein. The single-chain antibody has highly specific antigen recognition ability, and the fusion protein has both the specificity of the antibody. At the same time, it has excellent anti-tumor effect. It has obvious growth inhibitory effect on three different types of lung cancer cell lines. In animal experiments, the lung tumor tissue of mice can be significantly reduced compared with the control group. , and the antibody fusion protein has a small molecular weight and can be expressed in a prokaryotic cell expression system, which greatly reduces the production cost of antibody drugs.

Description

technical field [0001] The invention discloses a single-chain antibody and a fusion protein with hepcidin, belonging to the fields of immunology and molecular biology. Background technique [0002] Tumor is the biggest disease threatening human survival. According to a study by the World Health Organization, in 2012, the number of cancer cases in China was 3.065 million, accounting for about one-fifth of the global incidence; the number of cancer deaths was 2.205 million, accounting for about a quarter of the global cancer deaths. The formation and development of tumors have a very complex regulatory mechanism, and many biological effector molecules are involved. Clarifying the mechanism of action of these biological effector molecules is of great significance for the prevention and treatment of tumor diseases. In the prior art, it has been found that both Vascular Endothelial Growth Factor (VEGF) and hepcidin are involved in the regulation of tumor formation and developmen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/22C07K19/00A61K38/17A61K39/395A61P35/00
Inventor 满来谢珞琨李峥
Owner 北京格根生物科技有限公司